- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2017 Academic Article GET IT
- Health-related quality of life results from the phase III CheckMate 067 study. European journal of cancer (Oxford, England : 1990). 2017 Academic Article GET IT
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.
Molecular cancer therapeutics.
Times cited: 4
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015 Academic Article GET IT
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Cancer journal (Sudbury, Mass.).
Times cited: 12